HighTide Therapeutics (HKSE:02511) Total Assets : HK$869.59 Mil (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is HighTide Therapeutics Total Assets?

HighTide Therapeutics's Total Assets for the quarter that ended in Dec. 2023 was HK$869.59 Mil.

During the past 12 months, HighTide Therapeutics's average Total Assets Growth Rate was 271.90% per year.

Total Assets is connected with ROA %. HighTide Therapeutics's annualized ROA % for the quarter that ended in Dec. 2023 was -100.30%. Total Assets is also linked to Revenue through Asset Turnover. HighTide Therapeutics's Asset Turnover for the quarter that ended in Dec. 2023 was 0.00.

HighTide Therapeutics Total Assets Historical Data

The historical data trend for HighTide Therapeutics's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HighTide Therapeutics Total Assets Chart

HighTide Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Total Assets

953.41

955.71

869.59

HighTide Therapeutics Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23	Dec23
Total Assets	953.41	-	955.71	829.72	869.59

HighTide Therapeutics Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

HighTide Therapeutics's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (A: Dec. 2023 )	+	Total Liabilities (A: Dec. 2023 )
	=	768.679	+	100.914
	=	869.59

HighTide Therapeutics's Total Assets for the quarter that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (Q: Dec. 2023 )	+	Total Liabilities (Q: Dec. 2023 )
	=	768.679	+	100.914
	=	869.59

HighTide Therapeutics (HKSE:02511) Total Assets Explanation

Total Assets is connected with ROA %.

HighTide Therapeutics's annualized ROA % for the quarter that ended in Dec. 2023 is

ROA %	=	Net Income (Q: Dec. 2023 )	/	( (Total Assets (Q: Jun. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
	=	-852.19	/	( (829.722	+	869.594)	/ 2 )
	=	-852.19	/	849.658
	=	-100.30 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2023) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

HighTide Therapeutics's Asset Turnover for the quarter that ended in Dec. 2023 is

	Asset Turnover
=	Revenue (Q: Dec. 2023 )	/	( (Total Assets (Q: Jun. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
=	0	/	( (829.722	+	869.594)	/ 2 )
=	0	/	849.658
=	0.00

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

HighTide Therapeutics Total Assets Related Terms

Thank you for viewing the detailed overview of HighTide Therapeutics's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

HighTide Therapeutics (HKSE:02511) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » HighTide Therapeutics Inc (HKSE:02511) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

Ganli Second Road, 18B-102, Zhonghaixin Innovation Industry City, Jihua Neighborhood, Longgang District, Guangdong, Shenzhen, CHN, 518112

Website

https://www.hightidetx.com

HighTide Therapeutics Inc is a biopharmaceutical company specializing in the discovery, development and commercialization of multifunctional, multi-targeted therapies for the treatment of metabolic and digestive diseases. The company has developed a product pipeline of five product candidates in-house, covering nine indications in metabolic and digestive diseases among which, five are at clinical-stage. The Core Product, HTD1801 (berberine ursodeoxycholate), a new molecular entity, is a gut-liver anti-inflammatory metabolic modulator which targets multiple pathways pivotal to metabolic regulation, including those associated with metabolic and digestive diseases.

Executives

Ma Lixiong	2101 Beneficial owner
Liu Liping	2101 Beneficial owner
Li Li	2201 Interest of corporation controlled by you
The Core Trust Company Limited
Shan Miao	2201 Interest of corporation controlled by you
Medi Prosperity Capital Inc.	2201 Interest of corporation controlled by you
Hepalink Healthcare Partners I L.p	2201 Interest of corporation controlled by you
Hepalink Biotechnology Ii Limited	2101 Beneficial owner
Hepalink (hong Kong) Limited	2201 Interest of corporation controlled by you
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.	2501 Other
Wisdom Spring Group Limited
Tct (bvi) Limited
Baiyi Capital Limited	2101 Beneficial owner
Lai Hoi Man	2201 Interest of corporation controlled by you
Hongtu Capital Limited	2101 Beneficial owner

HighTide Therapeutics (HKSE:02511) Headlines

No Headlines